New Indication for Cancer Drug Crizotinib

Area of Science:

• Oncology
• Pharmacology

Background:

• Anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors are rare and often recurrent or refractory.
• Current treatment options for these specific tumors are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of crizotinib (Xalkori) for patients with ALK-positive inflammatory myofibroblastic tumors.
• To gain regulatory approval for crizotinib in this specific patient population.

Main Methods:

• The study involved adult and pediatric patients aged one year and older with recurrent or refractory ALK-positive tumors.
• Clinical trial data on efficacy and adverse events were assessed.

Main Results:

• Crizotinib (Xalkori) received Food and Drug Administration approval for this indication.
• Common side effects in adults include vision disorders, nausea, and edema.
• Pediatric patients experienced side effects such as vomiting, nausea, diarrhea, and rash.

Conclusions:

• Crizotinib is an approved targeted therapy for ALK-positive inflammatory myofibroblastic tumors in pediatric and adult patients.
• Understanding the adverse effect profile is crucial for patient management.